Her best-corrected visual acuity was counting fingers at 10-feet in the right eye and 20/30 in the left. Ophthalmoscopy revealed a disciform scar in the right eye, and centrally located geographic atrophy in the left eye. After 6 months, she developed subretinal choroidal neovascularization in the left eye that decreased her vision to 20/80. She was treated with intravitreal injection of pegaptanib, an aptamer that selectively inhibits VEGF-165 isoform, 2 and photodynamic treatment with verteporphyrin. A YAG-laser capsulotomy was also performed to maximize her visual gain.
Intravitreal injections of pegaptanib were repeated twice at 2 and 4 months, but her vision deteriorated to 20/300 at 7 months and she started to complain about itching. She was on no topical treatments at the time. Her anterior segment examination revealed the presence of deep stromal, branching crystalline-like deposits in the cornea OS (Figure 1a and b). No inflammation or epithelial defect was observed. Blood work to rule out systemic aetiology, including infectious, metabolic or lymphoproliferative disorders, serum protein electrophoresis, and lipid profile was unremarkable. The patient was diagnosed with a crystalline keratopathy, and the pegaptanib injections were discontinued. At 4 months after the cessation of treatment, the keratopathy spontaneously resolved.
Comment
Crystalline keratopathy is a rare condition characterized by epithelial and/or intrastromal crystalline opacities. It is most often caused by an infectious agent, particularly Streptococcus viridans, as a sequela of a surgical procedure, while on steroid therapy. 3 The time course of the appearance of the crystalline deposits after pegaptanib injections and their disappearance after holding the drug suggest a causal relationship, although another aetiology may be involved incidentally. Further, owing to our high suspicion, we did not reinject the patient with intravitreal pegaptanib. This case is the first to describe crystalline keratopathy after intravitreal injection of a VEGF inhibitor. 2, 4 We would like to caution that corneal side effects are possible, especially in pseudophakic patients, with open or broken capsular bags.
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